CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States

Feng, Xue; Farej, Ryan; Dean, Bonnie B.; Xia, Fang; Gaiser, Andrew; Kong, Sheldon X.; Elliott, Jay C.; Lindemann, Stefanie; Singh, Rakesh

doi:10.1016/j.xkme.2021.09.003

Cited by 11 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,3 For instance, at state level in the United States, the overall prevalence of non-dialysis-dependent CKD (stages G1-5) ranges from 2% or lower to 5% or higher in 2013. 6 Also in the current study, between SMAs that are the basic unit of community healthcare of the country, the rate of examinees under stage G3 showed wide deviation approximately from 5% to 15%. The wider regional difference in Japan may be due to even smaller unit size of Japan than that of state in the United States.…”

Section: Discussionsupporting

confidence: 46%

“…In addition, CKD prevalence is known to widely vary between countries or sometimes even regions in one country 2,3 . For instance, at state level in the United States, the overall prevalence of non‐dialysis‐dependent CKD (stages G1–5) ranges from 2% or lower to 5% or higher in 2013 6 . Also in the current study, between SMAs that are the basic unit of community healthcare of the country, the rate of examinees under stage G3 showed wide deviation approximately from 5% to 15%.…”

Section: Discussionmentioning

confidence: 99%

“…As a major public health problem nowadays, 9.1% of the global population are reported that are suffering from CKD 2 . In addition, the world faces great regional differences in the prevalence of CKD, possibly due to the prevalence of diabetes or hypertension, or the degree of socioeconomic development, 2–4 which could be true even in a single country 5,6 …”

Section: Introductionmentioning

confidence: 99%

“…2 In addition, the world faces great regional differences in the prevalence of CKD, possibly due to the prevalence of diabetes or hypertension, or the degree of socioeconomic development, [2][3][4] which could be true even in a single country. 5,6 In the early stages of CKD, patients tend to have minimal awareness of the disease. 7,8 However, whether CKD can be detected and treated in the asymptomatic early stage is crucial for the long-term survival of the patients.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Chronic kidney disease prevalence and awareness in middle age and young old: Regional comparative study in Japan

Nishi

Inoue

et al. 2023

Nephrology

View full text Add to dashboard Cite

Aim: Patients with chronic kidney disease are not aware of the illness because of its asymptomatic nature, but the association of disease progression and awareness in general population has not been sufficiently analysed on a large scale. Methods:We analysed the nationwide annual specific health checkup covering more than a half of the overall population at aged 40-74 in Japan, approximately 29.4 million people as of 2018, in combination with parameters to represent regional characteristics. Results:The rate of the examinees with kidney dysfunction, an estimated glomerular filtration rate of <45 mL/min/1.73 m 2 , was 1.0%, while that of examinees with of dipstick proteinuria ≥ (+) was 3.7%. Next, we conducted a regional comparative study on 335 medical administrative areas divided in the country. The regional rate of examinees aged 65-74 over the total examinees was positively correlated with the prevalence of kidney dysfunction (r = 0.72, p < .0001). Additionally, the mean rate of examinees aware of their 'chronic kidney failure' was 0.6%, and the awareness rate was correlated with the prevalence of both kidney dysfunction (r = 0.36, p < .001) and positive dipstick proteinuria (r = 0.31, p < .001) in those aged 65-74 at the regional level. Association of nephrology care resources with the prevalence or awareness was unclear at the regional level. Conclusion:We found a regional association of chronic kidney disease prevalence and awareness in a recent young old population in Japan. Further studies are needed to evaluate the patient screen and referral at the individual level.

show abstract

Section: Discussionsupporting

confidence: 46%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chronic kidney disease prevalence and awareness in middle age and young old: Regional comparative study in Japan

Nishi

Inoue

et al. 2023

Nephrology

View full text Add to dashboard Cite

show abstract

“…Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD) worldwide [1], with a prevalence of CKD caused by T2DM of around 130 million in 2019 and nearly 400,000 deaths and, as a result, imposing heavy medical and economic burden worldwide [2]. About 20-40% of patients with T2DM have CKD [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China

Zhang¹,

Xie²,

Hao³

et al. 2023

Kidney Dis

View full text Add to dashboard Cite

Background: This prespecified subgroup analysis of the FIDELIO-DKD trial aimed to evaluate the efficacy and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) in China. Methods: Three hundred and seventy-two participants were recruited from 67 centers in China and randomized 1:1 to oral finerenone or placebo with standard therapy for T2DM. The primary composite outcome included kidney failure, sustained decrease of estimated glomerular filtration rate (eGFR) ≥ 40% from baseline over at least 4 weeks, or renal death. The key secondary composite outcome included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Results: After a median follow-up of 30 months, the finerenone group showed a relative risk reduction (RRR) of 41% (hazard ratio [HR]=0.59, 95% confidence interval [CI], 0.39 to 0.88; p=0.009) for the primary composite outcome compared with placebo, consistent across its components with treatment benefits with finerenone. Based on an absolute between-group difference of 12.2% after 30 months, the number of patients who needed to be treated (NNT) with finerenone to prevent one primary outcome event was eight (95%CI: 4 to 84). For the key secondary composite outcome, the finerenone group showed a RRR of 25% (HR=0.75, 95% CI, 0.38 to 1.48; p=0.408). Adverse events were similar between the two groups. The effects of finerenone on blood pressure were modest. No gynecomastia events were reported in the study. Hyperkalemia leading to discontinuation occurred in eight (4.3%) and two (1.1%) participants in the finerenone and control groups, respectively. The incidence of acute kidney injury was comparable between the two groups (1.6% vs. 1.6%). Conclusions: Finerenone resulted in lower risks of CKD progression than placebo and a balanced safety profile in Chinese patients with CKD and T2DM.

show abstract

An In Silico Modelling Approach to Predict Hemodynamic Outcomes in Diabetic and Hypertensive Kidney Disease

Wang,

Benemerito,

Sourbron

et al. 2024

Ann Biomed Eng

View full text Add to dashboard Cite

Early diagnosis of kidney disease remains an unmet clinical challenge, preventing timely and effective intervention. Diabetes and hypertension are two main causes of kidney disease, can often appear together, and can only be distinguished by invasive biopsy. In this study, we developed a modelling approach to simulate blood velocity, volumetric flow rate, and pressure wave propagation in arterial networks of ageing, diabetic, and hypertensive virtual populations. The model was validated by comparing our predictions for pressure, volumetric flow rate and waveform-derived indexes with in vivo data on ageing populations from the literature. The model simulated the effects of kidney disease, and was calibrated to align quantitatively with in vivo data on diabetic and hypertensive nephropathy from the literature. Our study identified some potential biomarkers extracted from renal blood flow rate and flow pulsatility. For typical patient age groups, resistive index values were 0.69 (SD 0.05) and 0.74 (SD 0.02) in the early and severe stages of diabetic nephropathy, respectively. Similar trends were observed in the same stages of hypertensive nephropathy, with a range from 0.65 (SD 0.07) to 0.73 (SD 0.05), respectively. Mean renal blood flow rate through a single diseased kidney ranged from 329 (SD 40, early) to 317 (SD 38, severe) ml/min in diabetic nephropathy and 443 (SD 54, early) to 388 (SD 47, severe) ml/min in hypertensive nephropathy, showing potential as a biomarker for early diagnosis of kidney disease. This modelling approach demonstrated its potential application in informing biomarker identification and facilitating the setup of clinical trials.

show abstract

CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States

Cited by 11 publications

References 23 publications

Chronic kidney disease prevalence and awareness in middle age and young old: Regional comparative study in Japan

Chronic kidney disease prevalence and awareness in middle age and young old: Regional comparative study in Japan

Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China

An In Silico Modelling Approach to Predict Hemodynamic Outcomes in Diabetic and Hypertensive Kidney Disease

Contact Info

Product

Resources

About